CDC recommendations for opt-out HIV testing

JAMA

Volumn 301, Issue 3, 2009, Pages 274-

  Holtgrave, David R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; COUNSELING; DISEASE TRANSMISSION; EVIDENCE BASED PRACTICE; HEALTH CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFORMED CONSENT; LETTER; METRIC SYSTEM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; SERODIAGNOSIS; SURVIVAL TIME; HEALTH CARE PLANNING; MASS SCREENING; NOTE; RISK FACTOR; CLINICAL TRIAL; UNITED STATES;

AIDS SERODIAGNOSIS; HEALTH PLANNING GUIDELINES; HIV INFECTIONS; HUMANS; MASS SCREENING; RISK FACTORS; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; UNITED STATES;

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

EID: 58749115951     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.1007     Document Type: Letter

References (5)

1. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Optout testing for human immunodeficiency virus in the United States: progress and challenges. JAMA. 2008;300(8):945-951.
2. Kamb ML, Peterman TA, Wolitski RJ. Prevention counseling for HIV-negative persons. Am J Public Health. 2000;90(7):1152-1153.
3. Holtgrave DR, McGuire J. Impact of counseling in voluntary counseling and testing programs for persons at risk for or living with HIV infection. Clin Infect Dis. 2007;45(suppl 4):S240-S243.
4. Best-evidence interventions. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/hiv/topics/research/prs/print/best-evidence- intervention.htm. Accessed September 3, 2008.
5. Holtgrave DR. Costs and consequences of the US Centers for Disease Control and Prevention's recommendation for opt-out HIV testing. PLoS Med. 2007;4(6):e194.